Prof. Dr. med. Eicke Latz

2011 – 2023rnGroup leader, Innate Immunity in Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germanyrnrn2006 – 2013rnAssistant Professor of Medicine, Division of Infectious Diseases and Immunology, UMass Medical School, Worcester, MA, USArnrn2003 – 2006rnResearch Assistant Professor of Medicine, Division of Infectious Diseases and Immunology, UMass Medical School, Worcester, MA, USArnrn2001 – 2003rnPostdoctoral Fellow, Division of Infectious Diseases and Immunology, UMass Medical School, Worcester, MA, USArnrn1999 – 2001rnResearch Fellow, Molecular Sepsis Research Laboratories, Humboldt-University, Berlin, Germanyrnrn1998 – 2001rnInternship and Residency (Intensive Care), Department of Surgery, Charité University Hospital, Berlin, Germanyrnrn1998rnVisiting Scientist, Department of Lipid Biochemistry, Merck Research Laboratories, Rahway, NJ, USA

2001rnDoctorate, Medicine (Dr. med.), Free University of Berlin, Berlin, Germanyrnrn1998rnGerman Medical Licence Examination (State examination), License to practice Medicine (Approbation), Berlin, Germanyrnrn1995 – 2000rnUS Medical License Examinations I, II, III, Educational Commission for Foreign Medical Graduates, Philadelphia, USArnrn1991 – 1998rnStudies of Medicine, Georg-August-University Göttingen and Free University of Berlin, Berlin, Germany

Since 2024rnChief Innovation Officer, Charité – Universitätsmedizin Berlin, GermanyrnrnSince 2024rnMember, Innovation Board at Labor Berlin,  Germany.rnrn2023 – daternPortfolio Advisory Board (PAB) Member, IBT Lower Saxony, Germanyrnrn2022 – daternERC Panel Member, ERC starting grants, LS6 – Immunity, Infection and Immunotherapyrnrn2022 – daternMentor, Creative Destruction Lab (CDL)-Berlin, European School of Management and Technology (ESMT) Berlin, Germany.rnrn2021 – 2023rnElected Member, Supervisory Board of the University of Bonn (‘Hochschulrat’)rnrn2021 – 2023rnSpeaker, SFB 1454 “Metaflammation and Cellular Programming”, University of Bonnrnrn2018 – 2023rnCo-Speaker, Cluster of Excellence “ImmunoSensation2”, University of Bonnrnrn2016 – daternMember, Helmholtz Think Tank, Helmholtz Society, Berlinrnrn2015 – 2023rnChair of Scientific Advisory Board, MPI for Infection Biology, Berlin, Germanyrnrn2008 – daternConsultant (current and past): Novartis (Basel, Switzerland); Glaxo Smith Kline (London, UK); Medimmune (Gaithersburg, MD, USA); Biogen (Cambridge, MA, USA); Amgen (Seattle, WA, USA); Eisai Pharmaceuticals (Andover, MA, USA); Altana Pharmaceuticals (Konstanz, Germany); CBio Pharmaceuticals (Brisbane, Australia); Johnson u0026amp; Johnson (Brussels, Belgium); Boehringer (Ingelheim, Germany)rnrn2008 – 2016rnMember of Therapeutic Area Scientific Advisory Panels (TASAP): Inflammation u0026amp; Immunology, Centers for Therapeutic Innovation, Pfizer (Cambridge, MA, USA)rnrn2010 – 2023rnCommissions Head: BONFOR (intramural funding), Research Infrastructure; Commissions Member: Personnel u0026amp; Strategy, Finance, Core facilities; University of Bonnrnrn2005 – daternMember of Advisory Boards (current and past): Pfizer Worldwide R u0026amp; D (New York, NY, USA); Grünenthal Pharmaceuticals (Aachen, Germany); Genzyme (Boston, MA, USA); Opsona Pharmaceuticals (Dublin, Ireland)

German Society for Immunology (DGFI), American Association of Immunologists (AAI), International Trained Immunity Consortium (INTRIM), Founding member.

2023rnERC Advanced Research Grantrnrn2018rnGottfried-Wilhelm Leibniz-Prizernrn2016rnElected Member, German National Academy of Sciences (Leopoldina)rnrn2014-2023rnyearly Highly Cited Researcher in Immunology, ‘World’s Most Influential Scientific Minds’ (Thomson Reuters)rnrn2014rnKavli Fellow, United States National Academy of Sciences (NAS)rnrn2014rnERC Consolidator Grantrnrn2011rnGlaxo Smith Kline Clinical Science Awardrnrn2009rnDana Foundation Awardrnrn2004rnFOCIS Awardrnrn2001rnDAAD Postdoctoral Grant